AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Roche announces positive results with enfuvirtide.
2003 AUG 20 - (NewsRx.com & NewsRx.net) -- Fuzeon (enfuvirtide, formerly known as T-20), a drug that blocks the HIV virus from entering the human immune cell, could change the treatment options for pre-treated HIV patients.
World experts at the International AIDS Society (IAS), held in France, heard how the 24- and 48-week TORO (T-20 vs Optimized Regimen Only) 1 and TORO 2 data has confirmed that Fuzeon used with an optimized regimen of available HIV medication outperformed combinations comprised of the optimized regimen without Fuzeon.
Patients taking Fuzeon as part of their drug combination were twice as likely to achieve undetectable levels of HIV and even doubled their immune cell count increase versus those who did not take Fuzeon.
The Fuzeon containing regimen provided benefits across all sub-groups examined, including patients with few or no other treatment options. However, further analyses demonstrate that in the TORO study population at 24 weeks, the greatest magnitude of benefit is achieved when Fuzeon is used ...
- FUZEON(TM) Granted Priority Review Status by U.S. FDA.
- Press release article from: PR Newswire October 11, 2002 700+ words
...therapies continues to grow. FUZEON has the potential to help...The filing submission for FUZEON was based on 24-week data...TORO 2 (TORO: "T-20 vs. Optimized Regimen Only." In the TORO studies, combination therapy with FUZEON reduced HIV to undetectable...
- Fuzeon(R) Plus an Active Boosted Protease Inhibitor Doubles Long-Term Response...
- Press release article from: PR Newswire October 5, 2004 700+ words
...entering the cell. For this reason, Fuzeon is effective in treatment-experienced...patients may still develop resistance to Fuzeon. TORO Study Design: TORO 1 [T-20 (FUZEON) vs. Optimized Regimen Only] and TORO 2 are randomized, open...
- U.S. FDA Approves FUZEON(TM); First Drug to Block Entry of HIV into Immune...
- Press release article from: PR Newswire March 13, 2003 700+ words
...The regulatory submission for FUZEON was based on data from two 24...000 patients, TORO (T-20/FUZEON vs. Optimized Regimen Only) 1, conducted in North...experienced patients receiving FUZEON as a part of an optimized background...
- Latest Research on Fuzeon and T-1249, HIV Fusion Inhibitors, to be Presented At...
- Press release article from: PR Newswire February 10, 2003 700+ words
...immune cell. Consequently, FUZEON and T-1249 are active against...HIV drugs. Presentations on FUZEON -- Combined analysis of Phase...studies -- TORO 1 (T-20 vs. Optimized Regimen Only), conducted in North...experienced patients receiving FUZEON plus an individualized regimen...
- HIV Fusion Inhibitors FUZEON(TM) and T-1249 To Be Featured At 42nd Annual ICAAC.
- Press release article from: PR Newswire September 25, 2002 700+ words
...entering Phase II trials in 2003. FUZEON and T-1249 will be included...week) tolerability data from FUZEON Phase II clinical trials will...Phase III (TORO 1: T-20 vs. Optimized Regimen Only) FUZEON trial. (Slide Session 117...
- Following the Successful Development of FUZEON, Roche and Trimeris Sign...
- Press release article from: Business Wire January 5, 2004 700+ words
...entering the cell. For this reason, FUZEON is effective in treatment-experienced...patients may still develop resistance to FUZEON. TORO Study Design TORO 1 (T-20 (FUZEON) vs. Optimized Regimen Only) and TORO 2 are randomized, open...
- U.S. FDA Grants Traditional Approval for FUZEON(R), First and Only Fusion...
- Press release article from: PR Newswire October 15, 2004 700+ words
...entering the cell. For this reason, FUZEON is effective in treatment-experienced...patients may still develop resistance to FUZEON. TORO Study Design TORO 1 [T-20 (FUZEON) vs. Optimized Regimen Only] and TORO 2 were randomized...
- Second Pivotal Study Demonstrates Benefit of FUZEON(TM) Across Range of...
- Press release article from: PR Newswire November 18, 2002 700+ words
...24-week clinical data for FUZEON." New Analysis of TORO 2...analyses of TORO 2 (T-20/FUZEON vs. Optimized Regimen Only), presented in an oral...response of patients receiving FUZEON plus individualized background...
Source: HighBeam Research, Roche announces positive results with enfuvirtide.